Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The trial, which is a safety and efficacy study in onychomycosis (fungal nail infection and associated tinea pedis (athlete’s foot), began on March 28^th 2017, with primary and secondary endpoints expected to read out during the second half of this year.

BB2603 is an innovative new treatment concept using nanotechnology to deliver terbinafine, a potent antifungal, through the nail and into skin to treat fungal infection. This novel patented nanomedicine will initially be used to treat onychomycosis which is a highly infectious disease with a high medical need that is currently poorly managed by current treatments

Dr Mike Davies, Chief Medical Officer and Co-founder of Blueberry Therapeutics, said, “This is a great achievement by the team at Blueberry that has led to approvals and the start of our first clinical trial with BB2603 – our exciting, novel nanoformulation of terbinafine to treat onychomycosis and associated tinea pedis”

Progression of the lead product into the clinic has been a major step forward for Blueberry in the development of its lead topical anti-fungal. The resultant data will be used to support the opening of an Investigational New Drug Application in the US later this year in the United States.

John Ridden, CEO of Blueberry Therapeutics said, ‘This is an exciting time for Blueberry – we are making excellent headway in clinical development of BB2603 to establish its effectiveness in treating onychomycosis and […]

David gave a presentation to Manchester Metropolitan University as part of their Biomedical Away Day.

His presentation was on the Opportunities and Challenges in collaborating between Universities and Industry.

Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4^th April 2017.

In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead compound, BB2603, a novel nanoparticle formulation of terbinafine, to treat onychomycosis and tinea pedis.